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Abstract Influenza A virus is a pathogen of global medical
importance causing significant health and socio-economic
costs every year. Influenza virus is an unusual pathogen in
that it is pleomorphic, capable of forming virions ranging in
shape from spherical to filamentous. Despite decades of re-
search on the influenza virus, much remains unknown about
the formation of filamentous influenza viruses and their role in
the viral replication cycle. Here, we discuss what is known
about influenza virus assembly and budding, focusing on the
viral and host factors that are involved in the determination of
viral morphology. Whilst the biological function of the fila-
mentous morphology remains unknown, recent results sug-
gest a role in facilitating viral spread in vivo. We discuss these
results and speculate on the consequences of viral morphology
during influenza virus infection of the human respiratory tract.
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Introduction
Between 1918 and 1920, an estimated 50–100 million people
died from the first recorded pandemic of a viral infection com-
monly known as the flu [1]. This outbreak, nowadays known
as the Spanish flu, was caused by the Influenza Avirus (IAV).
Since 1920, IAV has continued to cause pandemics with the
most recent being the 2009 H1N1 swine flu pandemic [2]
which was estimated to have infected over 60 million people
and caused 12,000 deaths in the USA alone [3].
IAV is a pleomorphic virus of the Orthomyxoviridae family
consisting of a segmented, single stranded, negative sense
RNA genome [4]. Responsible for seasonal outbreaks and
occasional pandemics IAV is a major burden on health sys-
tems globally and is estimated to cost the US economy
$87.1bn annually [5]. Five to 15 % of the Northern hemi-
sphere’s population is estimated to be affected per annum [6]
with 250,000–500,000 deaths globally per year [7]. The most
severe illness occurs in immuno-compromised, elderly and
very young individuals and is often followed by secondary
bacterial pneumonia, resulting in significant morbidity and
mortality.
IAV infects the cells of the upper respiratory tract, causing
illness in a wide range of hosts, including humans, pigs, hors-
es and birds. Birds are thought to be the reservoir for IAV in
the wild [8] and are a key source for the emergence of novel
IAV strains [9], such as the 1918 Spanish flu. Recent strains
emerging from the wild bird population include the high path-
ogenicity avian influenza virus strains H5N1 and H7N9, cur-
rently circulating in Eastern Asia where they have up to a
60 % case-fatality rate in humans, though do not yet spread
efficiently from person to person [10].
The Influenza AVirus
The IAV genome comprises of 11 genes on eight RNA seg-
ments. These can broadly be categorised as encoding the viral
structural or non-structural proteins. Haemagglutinin (HA),
neuraminidase (NA), nucleoprotein (NP) and matrix proteins
one and two (M1 and M2) are primarily structural proteins
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with additional functional roles, whilst the polymerase sub-
units (PB1, PB2 and PA) and the non-structural proteins (NS1
and NS2) serve mainly function roles during virus replication.
NP binds to and is involved in the packaging of the viral
genome along with the polymerase subunits for transport
and assembly [11] and also interacts with various cellular pro-
teins, such as CRM1 involved in nuclear export of the repli-
cated viral genome [12]. HA is responsible for virus attach-
ment to a target cell by recognition of sialic acid residues on
the cell surface [13]. Following attachment, the virus un-
dergoes receptor-mediated endocytosis and subsequent
endosomal acidification triggers HA fusion activity wherein
HA mediates the fusion of the viral envelope with the
endosomal membrane, freeing the viral genome to traffic to
the nucleus [14]. NA has enzymatic activity, cleaving sialic
acid bonds and releasing newly formed viruses from the host
cell [15–17]. NA is the target of small molecule pharmaceuti-
cals used to treat influenza: Relenza® (zanamivir) and
Tamiflu® (oseltamivir) [18]. These are structural analogues
of sialic acid, and work to inhibit the enzymatic action of
NA, thus retaining newly formed virus on the host cells. HA
and NA are viral surface proteins and the main antigenic de-
terminants of the virus. Antigenic variations in HA and NA
give rise to the nomenclature ‘H’ and ‘N’ (e.g. H1N1). The
matrix proteins, M1 andM2, are formed from alternative read-
ing frames of RNA segment seven [19]. M1 is the most abun-
dant viral protein forming a scaffold beneath the host mem-
brane derived viral envelope. M1 anchors NA, HA and M2 in
place within the envelope and interacts with the viral genome
in the ribonucleoprotein (RNP) complex. M2 is a transmem-
brane ion channel protein, which plays a fundamental role in
the initial stages of viral infection. Once in the acidic endo-
some, M2 allows protons to enter the virus, triggering
uncoating [20] and the release of the viral RNP from M1
[21]. M2 also plays a pivotal role in IAV budding by altering
membrane curvature, facilitating the assembly of filamentous
virions and then mediating membrane scission and the release
of budding viruses [22].
Viral Assembly and Budding
It is thought that IAVassembly and budding occurs at lipid raft
domains on the apical surface of the host cell plasma mem-
brane, where IAV proteins are brought together in high con-
centrations within specific membrane regions [23]. NA and
HA are both fundamentally associated with these domains,
with the transmembrane domain of HA promoting the raft
association [24]. HA has the ability to induce budding of
virus-like particles (VLPs) in and of itself, forming vesicles
similar in appearance to viruses [25]. This suggests that HA
may possess an intrinsic capacity to alter membrane curvature.
Alternatively, the induction of membrane curvature may be
driven by the crowding of HA molecules within a defined
space (i.e. within a lipid raft domain). However, HA VLP
budding only produces spherical particles, whereas VLPs are
filamentous when M1 is also expressed [26••]. After the for-
mation of a viral bud, the virus remains attached to the host
cell through a small membrane neck. At this point, the M2
protein alters membrane curvature, constricting the neck and
causing membrane scission [27]. The enzymatic action of NA
can then release the fully formed virus from the host cell.
Throughout this process, it is not clear when the genome is
recruited to the budding virion nor the effects RNP binding
has on the budding process or the formation of filamentous
virions.
Viral Morphology
IAV is a pleomorphic virus, known to display a range of mor-
phological states, from filamentous to spherical, with ovoid or
bacilliform intermediates often observed (Fig. 1). In certain
cases, IAV strains may produce solely spherical virions; how-
ever, filament-producing strains always produce a mixture of
both filamentous and spherical virions. It is known that fila-
mentous viruses contain only one copy of the IAV genome,
thus each sphere, bacilliform or filament is thought to be a
single infectious unit regardless of length. Structurally, viral
filaments are roughly equal, or slightly smaller in diameter
(80–100 nm) to spherical virus (120 nm), but extend to a
significant length, sometimes upwards of 20 μm, with lengths
over 50 μm not unheard of. Filamentous viruses are particu-
larly of note as they are recurrently observed in human clinical
infections [28–34, 35••, 36] (for example, filamentous virions
are seen in lung sections from fatal cases of the 2009 H1N1
pandemic [37]). In contrast, many laboratory strains produce
solely spherical virions. The biological function of this
Fig. 1 Filamentous and spherical influenza virions. MDCK cells were
infected with 3 MOI of A/Udorn/72 influenza virus for 18 h. The
supernatant was harvested, fixed and processed for scanning electron
microscopy. Image is 14 x 20 μm
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morphology is not known nor is it understood how host adap-
tation can select for a specific viral morphology; however,
repeated passaging of filamentous human clinical isolates in
chicken eggs causes a morphological adaptation resulting in
the production of only spherical virus [28, 38] whereas adap-
tation to growth in guinea pigs restores filament formation
[35••]. Mutations of several different viral proteins can influ-
ence filament formation during the process of adaptation. For
example, the filamentous A/Udorn/72 strain becomes spheri-
cal with a single point mutation in the M1 protein [39–41].
Thus, a range of both host and viral factors governs the for-
mation of filamentous virions during influenza virus assembly
and budding.
Viral Determinants of Morphology
Many different studies have investigated the viral factors that
determine morphology, with most focusing on the structural
proteinsM1 andM2 and their role in viral assembly. M1 plays
a crucial role in the assembly and budding of both filamentous
and spherical IAV [23, 24]. In 2004, Elleman and Barclay
reported that M1 was also the main viral determinant of fila-
mentous morphology [42]. Swapping the ‘M’ RNA segment
from the spherical strain, A/Puerto Rico/8/1934 (PR8), with
the M segment of the filamentous strain, A/Udorn/1972
(Udorn), enabled the conversion of a spherical strain into a
filamentous strain (whenM-Udorn was inserted into PR8) and
a filamentous strain into a spherical strain (M-PR8 into
Udorn) [23, 40]. In 2007, Chen et al. showed that M1 is
required for the formation of filamentous VLPs, though it
was not required to form bacilliform (<1 μm) or spherical
VLPs [25, 43, 44].
Interestingly, in filamentous viruses, M1 appears to adopt a
helical conformation [14], which is not apparent in spherical
virus, suggesting that structural variations in the M1 protein
may govern viral structure [45]. As the most abundant viral
protein, M1 forms a layer under the viral envelope and is
responsible for interacting with NA, HA and M2 to form a
scaffold-like complex [46]. It is postulated that M2 can stabi-
lise this complex during budding to allow for continued M1
polymerisation and the formation of a viral filament [22, 47].
In support of this hypothesis, it has been observed that muta-
tion of the M2 protein can dramatically affect viral morphol-
ogy, with mutations in the c-terminal amphipathic helix
converting a filamentous virus into a spherical one [47],
whereas truncation of the c-terminus at residue 70 enables
filament formation from an otherwise spherical virus [48].
The effect of M2 on viral filament formation has also been
studied using the monoclonal antibody 14C2, which has been
shown to inhibit filamentous virus formation whilst permitting
spherical virus to bud [47]. 14C2 binds to the ectodomain of
M2 and is thought to disrupt the binding between the M2
cytoplasmic tail and M1 [47]. This is consistent with other
data showing that mutation of the M2 cytoplasmic tail be-
tween residues 70–77 reduces M1-M2 interactions and subse-
quently the amount of M1 and RNP packaged in virions [49,
50]. Intriguingly, a single amino acid substitution in the M2
cytoplasmic tail of the filamentous Udorn strain, Y76A, sig-
nificantly reduced the number and length of filamentous vi-
ruses produced [50]. However, recovery of the filamentous
morphology was seen with the addition of a S71Y mutation,
though it is not clear if these mutations also affect M1-M2
interactions [50]. In either case, it is possible that the M2
protein affects viral filament formation by altering membrane
curvature, stabilising the site of budding and therefore en-
abling M1 polymerisation and the elongation of a viral fila-
ment [18, 20]. Thus, M2 appears to modify filament formation
through binding and recruitment of M1, whereas M1 itself is
required for the actual structuring of the filament. This sug-
gests that filamentous virion production is likely a multi-
faceted process, affected by several different viral proteins,
all occurring in the context of an array of cellular partners.
Host Determinants of Morphology
IAV is pleomorphic, adopting both spherical and filamentous
forms [45]. As described, viral morphology can be altered
through adaptation to different hosts, implying that there are
host-specific influences on filament formation [35••].
Filamentous IAV is consistently found in human clinical iso-
lates from laboratory confirmed cases, in the 2009 H1N1 pan-
demic [37] and as far back as the 1957–1958 pandemic [38],
with the first identification having occurred in 1946 [51]. It is
known that filament forming strains become spherical after
repeated passage in embryonated chicken eggs, whereas the
filamentous morphology is retained during passage in Madin-
Darby canine kidney (MDCK) cells [28, 35••, 52]. Thus, host
cell factors play a considerable role in filament formation, and
IAV morphology may represent an adaptation to a specific
host cell environment. Previous research has identified several
host proteins that affect viral morphology. In particular, when
the Udorn virus is grown in polarised MDCK cells, filamen-
tous virus is produced from the apical plasma membrane [23,
24, 45]. Chemical disruption of the actin cytoskeleton causes
depolarization of the cells and specifically reduces filamen-
tous virus production whilst having no effect on the budding
of spherical virus [53]. Considering that the upper respiratory
tract consists of highly polarised epithelial cells and is the
primary site of human infection, the detection of filamentous
IAV in human clinical samples may be directly related to ep-
ithelial cell polarisation. However, other experiments have
shown that human embryonic kidney 293T cells are capable
of producing filamentous virions, despite an absence of cell
polarisation and a lack of a defined apical membrane [54].
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Thus, the impact of cell polarisation on viral morphology may
be more complicated and may be influenced by other host cell
proteins or processes.
In 2010, Bruce et al. reported that Rab11 and Rab11-family
interacting protein 3 (FIP3) are necessary for the formation of
filamentous virus [55]. Rab11 is a GTPase involved in the
recycling endosome pathway and plays a role in protein and
vesicle transport [56]. Rab11 is necessary for the budding of
all morphologies of IAV [54]; however, Rab11-FIP3 is essen-
tial for the formation of filamentous IAVs [55]. The FIPs reg-
ulate localisation and trafficking of target proteins [57] by
interacting with motor proteins, such as myosin Vb [58] and
kinesin [59]. FIP3 is involved in the regulation of Rab11 and,
subsequently, in several cellular pathways, such as the essen-
tial trafficking of endosomes to the cleavage furrow during
cytokinesis [60] and the regulation of actin filaments [57].
The polymerase subunit PB2 of the viral RNP complex inter-
acts with Rab11, which is complexed with cellular transport
vesicles and FIP3 [61, 62•]. RNPs then essentially ‘piggy-
back’ on these vesicles, travelling with Rab11 from the
MTOC to the site of virus budding along the microtubule
network [63]. Once near the plasma membrane, these RNP-
Rab11-vesicle complexes uncouple in an uncharacterized
mechanism, alluded to by the fact that budded virus (both
spherical and filamentous) are devoid of Rab11 [64]. It is
speculated that interactions with M1 are then responsible for
organisation of RNPs at the plasma membrane, as M1 is in-
trinsically associated with RNPs in late stage infection to pre-
vent their re-entry in to the nucleus [65]. It has not yet been
demonstrated, however, if the association with M1 uncouples
the Rab11-RNP complexes or if Rab11-transported vesicles
contribute any additional components to the budding virus.
One possible Rab11-associated component is FIP3, though
how this protein contributes to viral filament formation re-
mains unclear. However, it is apparent that the morphology
of IAV depends on both cellular and viral factors.
Functions of Viral Morphology
The biological significance of IAV morphology in human
clinical infections is a subject of great interest. The production
of viral filaments appears to be highly inefficient by its nature,
consuming anywhere from three to thirty times the amount of
plasma membrane used to bud one infectious virus [51, 53].
There are several opinions on why, despite this apparent inef-
ficiency, IAV readily produces filamentous virus in human
clinical infections. As there is always a mixed population of
spheres and filaments and never solely filaments, it is possible
that the two morphologies are playing different roles within
the host. It has been found that filament forming mutants of
PR8 have higher per-molecule NA activity in vitro [66••]. In
addition, NA has been shown to cleave sialic acid bonds
within the mucus secreted by airway epithelial cells [67, 68]
and the greater number of NA molecules (owing to a longer
viral length) may serve to more efficiently clear this mucus
layer. It is therefore plausible to think that the filamentous
morphology is actually a marker of pathogenicity in vivo,
whereby mucus in the airway is cleared by NA on filaments,
thus allowing for a more efficient spread of the smaller spher-
ical viruses [69]. This hypothesis is supported by a recent
study that suggests that filaments are not released as efficiently
as spheres from cells and may remain as cell-associated vi-
rions [44].
In 1998, it was shown that spherical and filamentous virus-
es are comparably infectious in vitro and both contain a single
copy of the viral genome [53, 69–71]. However, it has recently
been reported that certain subsets of filamentous virions may
lack a genome [69]. Vijayakrishnan et al. (2013) reported that
longer filaments were typically devoid of a copy of the viral
genome, whereas shorter filaments were not. Thus, there
might not be a single type of filamentous virions, but rather
a range, potentially with different functions. In the tightly
packed epithelial layer of the upper respiratory tract, short,
cell-anchored, infectious filaments may be able to directly
deliver the viral genome to neighbouring cells without the
need to release and transmit a viral particle. This process
may be facilitated by the more permissive use of
macropinocytosis as an alternate cell entry pathway, used by
filamentous IAV [72–74]. At the same time, longer, non-
infectious filamentous virions may serve to thin and clear host
respiratory mucus, facilitating the spread of spherical virions
to neighbouring cells and to new hosts.
Conclusions
In this review, we have explored recent findings in how IAV is
assembled and budded and how some of these mechanisms,
especially from a cellular aspect, may influence the budding of
filamentous IAV. Whilst many studies have found an effect of
cellular proteins and viral protein sequences on filament for-
mation, the causation and function of filamentous IAV re-
mains to be fully understood. What recent data shows for
certain is that IAV morphology is not solely cell or virus de-
pendent but relies on a precise balance and interaction be-
tween the two. A single point mutation in a viral protein can
alter morphology whereas silencing of a single cellular gene
can also affect the ability of an IAV strain to form filamentous
virions. Furthermore, a strain that forms filamentous virions in
vivo will not necessarily do so in vitro or in a different host
species. Ultimately, the role of filamentous IAV in human
infection remains an enigma. Given the resource requirements
needed to produce a single filamentous IAVas compared to a
single spherical virion, it is likely that the filamentous mor-
phology confers some advantage to the virus. Future
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investigations of IAV host-pathogen interactions will un-
doubtedly shed more light on the mechanisms of viral mor-
phogenesis, allowing for a better understanding of the mech-
anisms of influenza virus budding, the functions of viral mor-
phology and the impact of morphology on influenza disease in
human clinical infections.
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